Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1985 Jul;61(717):583–586. doi: 10.1136/pgmj.61.717.583

Ketanserin in essential hypertension: a double-blind, placebo-controlled study.

H A Cameron, L E Ramsay
PMCID: PMC2418322  PMID: 3161013

Abstract

The antihypertensive effect of the selective serotonin antagonist ketanserin was examined in a double-blind, placebo-controlled, parallel group study in 20 patients with essential hypertension. After 7 weeks treatment with ketanserin (mean dose 71 mg/d) there was a significant fall of both systolic and diastolic blood pressure, as compared to placebo, with a peak effect of 19.1/9.1 mmHg lying (P less than 0.01/P less than 0.01), and 16.5/11.3 mmHg standing (P less than 0.01/P less than 0.01); twice daily dosage appeared satisfactory. Subjective side effects were similar in the ketanserin and placebo groups. Ketanserin is an effective antihypertensive drug of moderate potency when given twice daily, with no orthostatic effect.

Full text

PDF
583

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson A., Morgan T., Dumpys R. The effect of ketanserin in essential hypertension. Clin Exp Pharmacol Physiol. 1983 May-Jun;10(3):331–333. doi: 10.1111/j.1440-1681.1983.tb00207.x. [DOI] [PubMed] [Google Scholar]
  2. Andrén L., Svensson A., Dahlöf B., Eggertsen R., Hansson L. Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist. Acta Med Scand. 1983;214(2):125–130. [PubMed] [Google Scholar]
  3. Ball S. G., Zabludowski J. R., Robertson J. I. Mechanism of antihypertensive action of ketanserin in man. Br Med J (Clin Res Ed) 1983 Oct 8;287(6398):1065–1065. doi: 10.1136/bmj.287.6398.1065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cohen M. L., Fuller R. W., Kurz K. D. Evidence that blood pressure reduction by serotonin antagonists is related to alpha receptor blockade in spontaneously hypertensive rats. Hypertension. 1983 Sep-Oct;5(5):676–681. doi: 10.1161/01.hyp.5.5.676. [DOI] [PubMed] [Google Scholar]
  5. De Crée J., Leempoels J., Geukens H., De Cock W., Verhaegen H. The antihypertensive effects of ketanserin (R 41468), a novel 5-hydroxytryptamine-blocking agent, in patients with essential hypertension. Clin Sci (Lond) 1981 Dec;61 (Suppl 7):473s–476s. doi: 10.1042/cs061473s. [DOI] [PubMed] [Google Scholar]
  6. Freestone S., Silas J. H., Ramsay L. E. Sample size for short-term trials of antihypertensive drugs. Br J Clin Pharmacol. 1982 Aug;14(2):265–268. doi: 10.1111/j.1365-2125.1982.tb01971.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hedner T., Persson B., Berglund G. Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension. Br J Clin Pharmacol. 1983 Aug;16(2):121–125. doi: 10.1111/j.1365-2125.1983.tb04974.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lund-Johansen P. Haemodynamics in essential hypertension. Clin Sci (Lond) 1980 Dec;59 (Suppl 6):343s–354s. doi: 10.1042/cs059343s. [DOI] [PubMed] [Google Scholar]
  9. PAGE I. H., MCCUBBIN J. W. The variable arterial pressure response to serotonin in laboratory animals and man. Circ Res. 1953 Jul;1(4):354–362. doi: 10.1161/01.res.1.4.354. [DOI] [PubMed] [Google Scholar]
  10. Peroutka S. J., Snyder S. H. Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Mol Pharmacol. 1979 Nov;16(3):687–699. [PubMed] [Google Scholar]
  11. Reimann I. W., Frölich J. C. Mechanism of antihypertensive action of ketanserin in man. Br Med J (Clin Res Ed) 1983 Aug 6;287(6389):381–383. doi: 10.1136/bmj.287.6389.381-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Reimann I. W., Okonkwo P. O., Klotz U. Pharmacokinetics of ketanserin in man. Eur J Clin Pharmacol. 1983;25(1):73–76. doi: 10.1007/BF00544018. [DOI] [PubMed] [Google Scholar]
  13. Somlyo A. P., Somlyo A. V. Vascular smooth muscle. II. Pharmacology of normal and hypotensive vessels. Pharmacol Rev. 1970 Jun;22(2):249–353. [PubMed] [Google Scholar]
  14. Zoccali C., Zabludowski J. R., Isles C. G., Murray G. D., Inglis G. C., Robertson J. I., Fraser R., Ball S. G. The effect of a 5-HT antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympathoadrenal function in normal man. Br J Clin Pharmacol. 1983 Sep;16(3):305–311. doi: 10.1111/j.1365-2125.1983.tb02166.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES